Iris Pharma of France, a specialist contract research organisation (CRO) for pre-clinical research in ophthalmology, mergered with Clirophtha, a unique CRO in Europe and North America that is completely dedicated to ophthalmology clinical trials. The new entity will be known as Iris Pharma. 

 

Iris Pharma of France, a specialist contract research organisation (CRO) for pre-clinical research in ophthalmology, mergered with Clirophtha, a unique CRO in Europe and North America that is completely dedicated to ophthalmology clinical trials. The new entity will be known as Iris Pharma.  The combined company will operate under the Iris Pharma name. This merger establishes the first global drug-development services provider to be totally dedicated to ophthalmology, offering a complete range of services to biotechnology and pharmaceutical companies worldwide.

The companies’ combined experience totals 31 years, with staff’s experience representing a combined total in excess of 260 years. This expertise will provide a one-stop solution for clients’ ophthalmology drug and device development; it will also create significant benefits for customers in terms of flexibility and efficiency.

Iris Pharma is an independent development service provider, dedicated to pre-clinical and clinical research in ophthalmology. Since 1989, it has been offering ophthalmologic drug and device development services to pharmaceutical and biotechnology companies worldwide. The company works in five complementary areas: bioanalysis; non-GLP pre-formulation; pre-clinical studies and services; clinical trials (Phase I to IV); and strategic consulting.  Iris Pharma will take part in the following trade shows: ARVO in Fort Lauderdale (USA) from 27 April to 1 May 2008 (Stand 109/111); BIO in San Diego (USA) from 17 to 20 June 2008; American Academy of Ophthalmology in Atlanta (USA) from 8 to 11 November 2008; and Bio-Europe in Mannheim (Germany) from 17 to 19 November 2008.